secwatch.observer — SEC 8-K summary
======================================

Issuer:     Panbela Therapeutics, Inc. (—)
CIK:        0001029125
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001437749-23-016196
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Panbela Therapeutics implements 1-for-30 reverse stock split effective June 1, 2023 to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split at 1:30 ratio reduces outstanding shares from ~16.8M to ~559,560; effective June 1, 2023.
- Split intended to increase per-share price to regain compliance with Nasdaq continued listing requirements.
- Certificate of Elimination filed to cancel sole outstanding Series A Preferred Stock share, as approved by stockholders.
- Stockholders ratified Cherry Bekaert as independent auditor and re-elected three Class I directors at May 25 annual meeting.
- No fractional shares issued; holders of fractional shares to receive cash in lieu.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/pbla20230530_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-016196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer